Revive Therapeutics Ltd. Announces Offering of Up to $3 Million
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN
TORONTO, Jan. 24, 2024 (GLOBE NEWSWIRE) — REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB:RVVTF) (“Revive” or the “Company”) announces that it is arranging a private placement of a maximum of 85,714,285 units (each, a “Unit”), at a price of $0.035 per Unit, for gross proceeds of up to $3 million (the “Offering”).
Related news for (RVVTF)
- Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
- Revive Therapeutics Advances with Next-Generation Bucillamine Development
- Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
- Revive Therapeutics Announces Proposed Shares for Debt Transaction
- Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment